From twst, July 2003. Dr. Frudakis: I can give you some projections. We think that total stockholders equity which is projected to be at $160,000 in 2004 will grow to $700,000 in 2005 and $12 million in 2006 based on our forensics business and our physical profiling, mainly the Taxol test I told you about. Property and equipment is going to grow as well. We have about $2 million worth of scientific equipment right now and that is going to grow to about $6 million in the next couple of years. Right now, every time we issue shares to raise funding, it counts as negative cash. Even though we have $200,000 in the bank and that amount stays pretty much constant because as it is spent, more is added in, if you look on the books, there is negative cash in the bank. That is because we have issued stock to pay for it. That will stay negative until 2006 when we think we will have about $8 million in cash. We project $60 million by 2007 based on all of the things happening that we talked about ' DNAprint's forensics' business continuing the growth it has, recreational business continuing the growth it has. This does not account for deals that help us become a pharmaceutical company, and if we acquire a pipeline with advanced candidates, both drug development expenses and winfall from a drug approval would significantly change these numbers. http://www.twst.com/notes/articles/tah617.html